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OBJECTIVE: To perform an economic evaluation (EE)
comparing eletriptan 40mg with available standard doses
of existing triptans in Spain using different outcome mea-
surements of anti-migraine effectiveness. METHODS:
A cost-effectiveness analysis was performed comparing
eletriptan (E) versus existing triptans available in Spain in
year 2002; sumatriptan (S), almotriptan (A), naratriptan
(N), rizatriptan (R) y zolmitriptan (Z). Effectiveness was
obtained from a meta-analysis of efﬁcacy with published
randomized clinical trials (RCT). Effectiveness measure-
ments were analgesic response within 2 hours (pain
reduction and pain free), usage of rescue medication, and
24 hours response (sustained pain free and recurrence
rate). Number needed to treat (NNT), with its 95% con-
ﬁdence interval was calculated. EE was performed from
the National Health System perspective and drugs cost
are computed only using public selling prices. RESULTS:
A total of 33 RCTs were used to ascertain triptans effec-
tiveness (9.473 patients treated with triptans and 3.432
with placebo). The proportion of patients with headache
response within 2 hours was higher with eletriptan than
with the rest of triptans; 38% versus, respectively, 28%,
25%, 23%, 37%, & 25% for S, Z, N, R, and A. E
showed a lower NTT per successfully treated attacks than
comparators; 2,6 vs, respectively, 3.6, 4.0, 4.3, 2.7, 4.0,
and 2.6. The cost per successfully treated patient was
lower for E; €26.54 versus €30.61, €45.95, €29.69,
€32.41, and €36.06. CONCLUSIONS: The cost per suc-
cessfully treated migraine attack was lower for patients
treated with Eletriptan compared to other existing trip-
tans in Spain.
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OBJECTIVES: To assess the cost-effectiveness of nasal
spray zolmitriptan 5mg (ZOL), compared to subcuta-
neous sumatriptan 6mg (SUM) in the management of
moderate to severe migraine patients in Belgium.
METHODS: A medical decision analytic model was
developed in MS-Excel, reﬂecting patient outcomes and
related management. The net response rate (headache
response after 2 hours) above placebo is a primary
outcome in migraine trials and was obtained from ran-
domised clinical trials. This response rate above placebo
was 52% for SUM, and 39.7% for ZOL. However, recur-
rence rates after initial response and within the same
attack were 39% and only 25.6% respectively. Cost of
non-response and cost of managing recurrence were
obtained from published local literature from a health
care payer perspective. Full response was deﬁned as
patients responding without recurrence. The time horizon
was limited to one attack episode. RESULTS: ZOL total
treatment cost was €28.02 with 43.7% full response,
while SUM costed €40.95 in total with 42.19% full
response (i.e. ZOL slightly dominant). Rank order sta-
bility analyses (ROSA) showed that results were very
robust towards variations in cost of management (max.
deviation in savings of 4%). The analysis was sensitive to
treatment performance and recurrence rates, both having
a weak effect on savings (max deviation in savings of
13%), but with the potential to inverse the dominant
position of ZOL. CONCLUSIONS: ZOL as standard
treatment in moderate to severe migraine is cost saving
from the Belgian health care payer’s perspective compared
to SUM, with comparable effectiveness.
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OBJECTIVE: In Canada, the clinical use of triptans is
restricted by many health plans, despite their proven
superior efﬁcacy in the treatment of moderate to severe
migraine. This analysis estimates the clinical conse-
quences, costs and cost-effectiveness of Rizatriptan com-
pared to other triptans and UC in Ontario, Canada.
METHODS: A decision analytic model was created to
estimate migraine treatment costs and clinical outcomes
observed over a 24-hour period from therapy initiation,
in patients with a diagnosis of moderate to severe
migraine as deﬁned by International Headache Society
(IHS) criteria. Efﬁcacy measures consisted of pain-free
patients at 2 and 4 hours and those sustained pain-free
for the following 2 to 24 hours. Rizatriptan was com-
pared to other triptans based on data from a meta-
analysis, and compared to UC based on other published
data. Costs of therapies were used to determine incre-
mental costs per attack aborted as well as cost per QALY.
Both a Ministry of Health perspective (direct costs) and
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a societal perspective (direct and indirect costs i.e. time
loss from paid and unpaid work) were included. One-way
sensitivity analyses were conducted to validate the robust-
ness of the model. RESULTS: Cost estimates are similar
to the previously published Canadian studies. Rizatriptan
compared to UC produced a cost per QALY gained of
$31,845. When the societal perspective was considered
the cost per QALY decreased to $5263. Rizatriptan had
a substantial advantage over UC in pain-free results at 2
and 4 hours, resulting in a modest incremental costs of
$49.82 and $58.48 per attack aborted respectively. In
addition, Rizatriptan dominated all other triptans on all
measures considered; it was both more effective and less
costly. CONCLUSION: This study shows that treatment
with Rizatriptan for patients who suffer from moderate
to severe migraines constitutes a cost-effective strategy for
improving care of migraine patients in Canada.
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OBJECTIVES: To determine the resource use and costs
of managing chest and CNS-related adverse events (AE)
of oral triptans in Spain. METHODS: Incidence rates of
AE were obtained from a recent meta-analysis of clinical
trials (Ferrari et al. Cephalalgia 2002). A panel of six neu-
rologists with extensive experience in migraine treatment
with triptans was asked how Spanish patients react when
they experience triptan AE, and how physicians manage
those patients who seek medical attention. All resources
used in AE management were valued (in 2002 Euros)
using unit costs retrieved from local databases.
RESULTS: If the triptan is prescribed by a general prac-
titioner (GP), 19.2% of patients will see a physician when
experiencing chest-related AE, while 18.3% will do so in
the case of CNS-related AE. For patients receiving triptan
prescription from specialists, these rates are 9.2% and
13.3%, respectively. Resource consumption comprises
visits to physicians and emergency departments (EDs),
electrocardiograms, cardiac enzymes, and chest radiogra-
phy. The cost of managing a consulting patient for chest-
related AE is €33.09, €66.43, or €137.01, when treated
by a GP, a specialist or at an ED, respectively. For CNS-
related AE, costs amount to €16.89, €52.88 and €102.17,
respectively. After correction for non-consulting patients
and allowing for the different routes of consultation,
average cost per chest- and CNS-related AE is €16.76 and
€5.05, respectively. Considering placebo-subtracted inci-
dence rates, the management of AE adds between €0 (for
almotriptan 12.5mg) and €1.17 (for eletriptan 80mg) to
the average cost of treating a migraine episode with trip-
tans. CONCLUSIONS: Although triptans are well toler-
ated and most Spanish patients who experience an AE
will not consult a physician, the management of AE can
add signiﬁcant costs to triptan treatments. Consequently,
more tolerable triptans (like almotriptan 12.5mg) should
not only be favored on clinical grounds but also for eco-
nomic reasons.
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OBJECTIVE: As the second most common primary
headache, it follows that migraine is associated with sub-
stantial clinical and economic consequences. Migraine
particularly impacts the labor force as its disabling effects
frequently persist beyond the acute onset of an attack.
With such effects in the work place, further understand-
ing of the losses in productivity as a result of migraine is
necessary. The objective of this study was to determine
the indirect costs due to migraine in the U.S. population.
METHODS: Retrospective analysis was conducted of the
1999 portion of the Medical Expenditure Panel Survey
(MEPS). The MEPS provided data from a nationally rep-
resentative sample of 24,618 respondents and data from
respondents’ medical care and health insurance providers
and employers. Data utilized in this study included
medical conditions and employment information com-
prised of hourly earnings, hours worked, and disability
days. Migraine patients who incurred disability days were
identiﬁed using International Classiﬁcation of Diseases
(ICD-9-CM) codes and variables denoting disability days.
Indirect costs were calculated for migraineurs who missed
workdays using the human capital approach. Sample esti-
mates were weighted and projected to the population and
95% conﬁdence limits for estimates were calculated using
the Taylor expansion method. RESULTS: Total indirect
costs of migraine patients who missed workdays were
$3,895,041,461, with mean indirect costs of $2,273 per
patient (95% C.L. = $1,665 to $2,882). Relative to 
the entire population, mean indirect costs per person 
were $14. CONCLUSIONS: With total indirect costs
approaching $4 billion and per patient indirect costs
greater than $2000, migraine continues to have a con-
siderable impact on the work force. Additional steps
should be undertaken to further develop diagnostic and
treatment paradigms in an effort to reduce migraine-
related absenteeism and lost productivity.
